- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03437330
Empagliflozin Effect on Glucose Toxicity
Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The EMPA-REG outcome trial showed that empagliflozin on top of standard therapy for Type 2 diabetes mellitus (T2DM) resulted in superiority in terms of the primary composite cardiovascular endpoint (hazard ratio (1) = 0.86; 95% confidence interval [CI] 0.74-0.99; P value = 0.04), hospitalization for heart failure (-35%), cardiovascular mortality (-38%) and all-cause mortality (-32%, each p < 0.001) (2). This reduction in mortality is not fully explained by the reduction in HbA1c, body weight, waist circumference and blood pressure in the empagliflozin groups versus the placebo group. Differences in mode of action of empagliflozin compared to standard therapy might, thus, help to explain why empagliflozin was so efficient in reducing cardiovascular death.
The aim of the present study is to provide evidence for a reduction of skeletal muscle H2O2 levels, and consequently improvement in mitochondrial function, and restored methylation pattern of key transcription factors in skeletal muscle from patients with T2DM when treated with empagliflozin versus insulin glargine as the prototypical medication favoring glucose uptake into tissues. It is hypothesized that empagliflozin compared to insulin specifically reduces H2O2 concentrations in skeletal muscle of patients with T2DM, because it leads to excretion of glucose and lower glucose uptake in skeletal muscle (22), while insulin shifts the major part of excess glucose into skeletal muscle cells.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Tuebingen, Baden-Württemberg, Germany, 72076
- University Hospital
-
-
North Rhine Westphalia
-
Duesseldorf, North Rhine Westphalia, Germany, 40225
- German Diabetes Center, Leibniz-Center for Diabetes Research at the Heinrich-Heine-University Duesseldorf
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must fulfill all of the following criteria before inclusion in the study:
- The informed consent form must be signed before any study specific tests or procedures are done
- Male or female patients aged between 40 and 70 years (including) at the first screening visit
- Patients diagnosed with T2DM
- HbA1c between 7-9% (including)
- Stable treatment with antidiabetic drugs over the last 4 weeks
Accepted background medication:
- Metformin up to 2000 mg per day and/or
- DPP-IV inhibitors:
Linagliptin up to 5 mg per day Sitagliptin up to 100 mg per day Vildagliptin up to 100 mg per day Saxagliptin up to 5 mg per day
- Body mass index (BMI) between 25 and 40 kg/m2 (including)
- Ability to understand and follow study-related instructions
- No clinical relevant abnormalities during ECG and cardiac examinations
Exclusion Criteria:
Subjects are to be excluded from the study if they display any of the following criteria:
- Unstable Angina pectoris, myocardial infarction or stroke within 1 year before inclusion in the study
- History of atrial fibrillation
- Uncontrolled arterial hypertension (> 160/100 mmHg in three subsequent measurements - mean value)
- eGFR < 60 ml/min/1.73 m2
- Macroalbuminuria defined as ≥ 300 mg albumin / 24h urine
- Triglyceride > 250 mg/dl
- Genetic muscle disease
- Known coagulation disorder
- Treatment with anti-platelet therapy and anticoagulation which cannot be paused for medical reasons
- Treatment with anticoagulants within 7 days prior to the muscle biopsy
- Contraindications according to the local SmPC of Lantus® or Jardiance® (see Appendix 1)
- History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure or to the local anesthetic scandicaine or lidocaine
- Addiction or other diseases that preclude the patient from appropriately assessing the nature and scope as well as possible consequences of the clinical study
- Pregnant or breast-feeding women
Women of childbearing potential unless women who meet the following criteria:
- Post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum follicle-stimulating hormone [FSH] > 40 U/mL)
- Postoperatively (six weeks after bilateral ovariectomy with or without hysterectomy)
- Regular and correct use of a contraceptive method with error rate <1% per year such as implants, depot injections, oral contraceptives or intrauterine devices
- Sexual abstinence
- Vasectomy of the partner
- Males must agree not to father a child and to refrain from donating semen or sperm while participating in the study and for 90 days following discontinuation from this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empagliflozin (Jardiance®)
Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral
|
Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs)
|
Active Comparator: Insulin Glargine (Lantus®)
Thus, insulin glargine doses should be adapted as follows: FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +3 IU FBG > 8 mmol/L: +5 IU |
insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows: FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in skeletal muscle H202 concentration between baseline and end of treatment (EoT)
Time Frame: 12 weeks
|
The primary objective is to investigate the change in H2O2 concentration as a read out of reactive oxygen species (ROS) production in skeletal muscle biopsies from T2DM patients before and after treatment with empagliflozin or insulin glargine.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary objectives of the study are to evaluate the effect of empagliflozin and insulin glargine on glucose toxicity in skeletal muscle by investigating
Time Frame: 12 weeks
|
Change in skeletal muscle mitochondrial function (O2consumption) between baseline and EoT
|
12 weeks
|
Change in skeletal muscle lipid peroxidation
Time Frame: 12 weeks
|
Change in skeletal muscle lipid peroxidation between baseline and EoT
|
12 weeks
|
Change in 24-hour urinary excretion rate of 8-iso PGF2a
Time Frame: 12 weeks
|
Change in 24-hour urinary excretion rate of 8-iso PGF2a between baseline and EoT
|
12 weeks
|
• Difference in DNA methylation pattern
Time Frame: 12 weeks
|
• Difference in DNA methylation pattern between the treatment groups at EoT
|
12 weeks
|
Change in plasma FFA levels
Time Frame: 12 weeks
|
Change in plasma FFA levels between baseline and end of trial
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Oxidise
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes Mellitus
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
Hamad Medical CorporationQatar Computing Research Institute (QCRI); Droobi HealthUnknown
-
Boryung Pharmaceutical Co., LtdRecruiting
-
Georgia Institute of TechnologyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory...CompletedType2 Diabetes MellitusUnited States
-
EMSWithdrawnType2 Diabetes Mellitus
-
TheracosCompletedType2 Diabetes MellitusUnited States
-
Chong Kun Dang PharmaceuticalUnknown
-
Chong Kun Dang PharmaceuticalUnknownType2 Diabetes MellitusKorea, Republic of
Clinical Trials on Empagliflozin (Jardiance®)
-
Handok Inc.CompletedType 2 Diabetes MellitusKorea, Republic of
-
Boehringer IngelheimEli Lilly and CompanyActive, not recruiting
-
Boehringer IngelheimRecruitingHeart FailureKorea, Republic of
-
University of PennsylvaniaRecruitingHeart Failure With Preserved Ejection FractionUnited States
-
Pharma NuevaNot yet recruiting
-
China National Center for Cardiovascular DiseasesRecruitingHypertension | Pre-Heart FailureChina
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
National Taiwan University HospitalShin Kong Wu Ho-Su Memorial HospitalNot yet recruitingHeart Failure With Reduced Ejection Fraction | End Stage Renal Disease on Dialysis
-
Boehringer IngelheimRecruitingKidney Disease, ChronicKorea, Republic of
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan